Idrasil
Idrasil is a U.S. medical cannabis manufacturer producing Idrasil™, a standardized full-spectrum cannabis tablet sold via physician prescription to patients with chronic pain, sleep disorders, ADHD, and cancer.
- Company typePrivate
- Founded2020
- HeadquartersAnaheim, United States
- Headcount11–50
- GTM typeB2C
- OfferingHardware or Manufacturing
What Idrasil does
Idrasil is a U.S.-based manufacturer of standardized medical cannabis products, operating under its parent company CS® International, Inc. and headquartered in Anaheim, California. The company's flagship product is Idrasil™, a prescription medical cannabis tablet offered in 12.5mg, 25mg, and 100mg dosages. The product is positioned as a full-spectrum alternative to synthetic single-molecule THC pharmaceuticals (such as Marinol), reportedly containing 65+ cannabinoids produced through a proprietary extraction process in a sterile laboratory environment. Idrasil is privately held with an estimated 11-50 employees.
The business model is prescription-based and direct-to-patient, requiring physician involvement at the point of sale. Customers follow a six-step process: pre-order, physician consultation, prescription issuance, order submission, delivery, and ongoing benefits management. Target patient populations include those with chronic pain, sleep disorders, ADHD, and cancer (for chemotherapy support), positioning Idrasil within physician-supervised therapeutic pathways rather than recreational cannabis retail. The go-to-market relies on a physician prescription network and a direct website ordering channel (idrasilrx.com), with awareness supported by a presence on LinkedIn, X (Twitter), Facebook, and Instagram, and earned media coverage in outlets such as AlleyWatch, Benzinga, and Yahoo Finance.
No revenue, funding, management, or AI/ML capability disclosures are present in the available data. The company operates a single product line with a relatively friction-heavy distribution model that depends on patient-physician engagement and is not currently positioned for OTC or dispensary retail channels.
Idrasil firmographics
Firmographics- Name
- Idrasil
- Legal name
- CS® International, Inc.
- Website
- https://idrasilrx.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Idrasil is a U.S. medical cannabis manufacturer producing Idrasil™, a standardized full-spectrum cannabis tablet sold via physician prescription to patients with chronic pain, sleep disorders, ADHD, and cancer.
- Ownership category
- akta.pro rank
Idrasil industry classification
Industry- Product category
- Medical Cannabis Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services) (CRANAFAI)
Keywords
Where Idrasil is headquartered
LocationHeadquarters
- HQ city
- Anaheim
- HQ country
- United States
- HQ region
- North America
Markets served
Idrasil business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Marketing or Sales, Technology or R&D, Personnel
Revenue model
- Medical Cannabis Tablet Sales: Revenue generated from sale of standardized medical cannabis tablets in three dosage strengths (12.5mg, 25mg, 100mg) through a prescription-based direct-to-patient model
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Standard dosage tiers: 12.5mg, 25mg, 100mg |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels7 records
Idrasil product offering
Product offeringCore offering
Idrasil™ is a standardized, prescription-only medical cannabis tablet available in 12.5mg, 25mg, and 100mg scored dosage strengths, manufactured in a sterile laboratory from cloned cannabis plants using proprietary extraction that yields a pure natural extract containing over 65 naturally occurring cannabinoids. The product is positioned as a non-smoking, non-addictive, non-opioid analgesic alternative to traditional pain medications and is dispensed to individual patients through a physician-supervised pre-order and prescription fulfillment process.
Product overview
Idrasil™ is a single pharmaceutical product—a standardized medical cannabis tablet available in three dosages (12.5mg, 25mg, and 100mg). The product is manufactured in a sterile laboratory and provides all-natural cannabis plant extract containing over 65 cannabinoids, distinguishing it from synthetic single-cannabinoid alternatives like Marinol (Dronabinol). The company offers the product directly to patients via a membership/pre-order model with physician prescription requirements.
Differentiator
Problem solved
Functional benefit
Products and services
- Idrasil™ Medical Cannabis Tablets Prescription-only, standardized medical cannabis tablet manufactured from cloned cannabis plants using a proprietary extraction process, available in 12.5mg, 25mg, and 100mg scored dosage strengths and containing over 65 naturally occurring cannabinoids; marketed to patients with a licensed physician's prescription for pain management, sleep disorders, ADHD symptom management, and chemotherapy side effect relief.
Quantifiable outcome
- D. Chambers achieved 85% pain reduction (from 100% to 15%) with 1.5 tablets
- +1 more outcomes
Companies that use Idrasil
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles4 records
Idrasil technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Idrasil partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- C3 International, Inc.coreC3 International, Inc. is the parent company producing Idrasil. The company is referred to as 'CS International, Inc.' in footer. They provide manufacturing, patient services email support, and corporate backing for the Idrasil brand.
Scale indicators2 records
Recent moves6 records
Expansion highlights4 records
Idrasil competitors and assessment
Company assessmentDirect peers
- Canopy Growth: Canopy Growth's medical cannabis division (Spectrum Therapeutics) offers capsules, oils, and oral dosage forms targeting chronic pain, sleep, and other therapeutic areas — overlapping Idrasil's patient segments with greater scale and brand recognition.
- Curaleaf Holdings: Curaleaf is a US multi-state medical and adult-use cannabis operator with capsule and tablet formats, directly comparable in clinical positioning and patient focus to Idrasil, with substantially larger retail and distribution footprint.
- Trulieve Cannabis: Trulieve is a US-focused medical cannabis operator with standardized capsule and oral products serving chronic pain, sleep, and other therapeutic indications, overlapping Idrasil's patient segments with much greater scale.
- Columbia Care: Columbia Care operates medical cannabis dispensaries and produces standardized oral dosage forms across multiple US states — a clinical-format peer to Idrasil with stronger pharmacy-channel distribution.
- Vireo Health (Goodness Growth Holdings): Vireo Health operates a pharma-style medical cannabis business with standardized oral formulations, explicitly physician-focused positioning — directly comparable to Idrasil's clinical, prescription-based model.
- Aurora Cannabis: Aurora Cannabis produces medical cannabis capsules and softgels in standardized doses, directly paralleling Idrasil's standardized tablet approach. Competes in patient segments including chronic pain and chemotherapy support.
- Tilray Brands: Tilray is a major global cannabis company with medical cannabis product lines including capsules and oral formulations, directly comparable to Idrasil's standardized tablet approach. Operates with substantially greater capital and distribution across multiple geographies.
Others
- Solvay Pharmaceuticals (Marinol / Dronabinol): Marinol (Dronabinol) is the synthetic single-THC pharmaceutical that Idrasil explicitly positions against on its website. Marinol represents the legacy pharmaceutical-format cannabis alternative — a comparable pharmaceutical cannabis product Idrasil seeks to displace.
Broad incumbents
- Jazz Pharmaceuticals: Jazz Pharmaceuticals markets Epidiolex, the first FDA-approved plant-derived CBD pharmaceutical, and is a direct cannabis-pharmaceutical comparator to Idrasil's clinical cannabis tablet positioning. Demonstrates the FDA pathway Idrasil could pursue at scale.
Emerging players
- CV Sciences (PlusCBD): CV Sciences sells standardized CBD oral products through retail and practitioner channels with pharmaceutical-style branding, comparable to Idrasil in clinical positioning though focused on hemp-derived CBD rather than full-spectrum medical cannabis.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Idrasil social profiles
Digital presenceIdrasil financial estimates
Financial estimateRevenue estimate
Valuation estimate
Idrasil leadership team
Management profileNumber of profiles
Idrasil funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Idrasil M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Idrasil
What does Idrasil do?
Idrasil™ is a standardized, prescription-only medical cannabis tablet available in 12.5mg, 25mg, and 100mg scored dosage strengths, manufactured in a sterile laboratory from cloned cannabis plants using proprietary extraction that yields a pure natural extract containing over 65 naturally occurring cannabinoids. The product is positioned as a non-smoking, non-addictive, non-opioid analgesic alternative to traditional pain medications and is dispensed to individual patients through a physician-supervised pre-order and prescription fulfillment process.
Is Idrasil a public or private company?
Idrasil is a private company. It is classified as corporate owned and is currently operating.
When was Idrasil founded?
Idrasil was founded in 2020. It employs 11 to 50 people.
Where is Idrasil based?
Idrasil is headquartered in Anaheim, United States, in the North America region.
How does Idrasil make money?
One revenue line is on record: medical Cannabis Tablet Sales.
Who are Idrasil's main competitors?
Direct peers on record are Canopy Growth, Curaleaf Holdings, Trulieve Cannabis, Columbia Care, Vireo Health (Goodness Growth Holdings), Aurora Cannabis and Tilray Brands. Solvay Pharmaceuticals (Marinol / Dronabinol) is listed as an others. Jazz Pharmaceuticals is listed as a broad incumbent. CV Sciences (PlusCBD) is listed as an emerging player.
Does Idrasil have an API?
No public API is recorded for Idrasil.
What industry is Idrasil in?
Idrasil's product category is Medical Cannabis Pharmaceuticals. Its primary akta.pro industry code is CRANAFAI, Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services). Its NAICS code is 325412 and its SIC code is 2834.